Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

bert A. Harrington, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Clinical Research Institute. "I'm looking forward to seeing data from phase II and phase III studies with the REG1 drug:antidote system."

"The data from the Phase 1c study addressed important questions, particularly regarding the ability to titrate the RB007 component and therefore 'dial down' the anticoagulant effect of RB006," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Based upon our Phase I study results, we developed an extensive Phase II program to evaluate REG1 in a variety of coronary revascularization settings. The first study is actively enrolling patients and we expect to initiate several additional studies over the coming months."

REVERSAL-PCI, a multi-center, open-label, randomized Phase IIa clinical study of the REG1 anticoagulation system, will enroll 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct- acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant co
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Today, UBM China, a ... agreement with Chengdu Tianyi Exhibition Co., Ltd. to jointly ... is to be held concurrently with CWMEE 2016. ... healthcare exhibition family, following MEDTEC China and DENTECH China, ... in west China. It,s also another concrete cooperative project ...
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of 40,229,886 units. Each unit consists of one share ... to purchase one share of common stock, and 0.50 ... of common stock, at a purchase price of $0.87 ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:6/30/2015)... ... ... Trenton Health Team has been certified by the New Jersey Department of ... State, serving the greater Trenton community. The ACO pilot is for a three-year ... collaborative structure of THT, bringing together the vast majority of Trenton’s primary and specialty ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... rating in a new video, “Grand Terrace Health Care Center.” Each year, Medicare ... and help patients find the best facility for their needs. Grand Terrace prides ...
(Date:6/30/2015)... ... 2015 , ... University Post-Acute Rehab recently released a video ... center’s patients and their experiences at the facility. Medicare granted University Post-Acute Rehab ... patient attests to the high rating, which is predominantly based on cleanliness, employees, ...
(Date:6/30/2015)... ... June 30, 2015 , ... On June 26, 2015, ... ,” listed five triggers that most people would not expect to cause acne ... toothpaste. The primary causes of acne are clogged pores and bacteria and ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... with autism will likely decrease if a new definition of ... year. Doctors aren,t sure what the implications of the ... impact on the lives of people with autism and the ...
... Boston (Jan. 23, 2012) Research to Prevent Blindness ... of Harvard Medical School, a $30,000 Medical Student Eye Research ... Shah. The award will allow Ms. Shah to participate ... Glaucoma Service Director Dr. Louis Pasquale in collaboration with Dr. ...
... Chronic inflammation combines with DNA methylation, a process that ... cancer, scientists at The University of Texas MD Anderson ... of the journal Nature Medicine . The ... lead to better combination therapies for treating and preventing ...
... III colon cancer patients in the general population who receive ... survival when oxaliplatin is added to 5-fluorouracil (5FU), according to ... the National Cancer Institute . Colon cancer is a ... estimated 101,340 cases among Americans in 2011. Roughly one third ...
... Hopkins Center for Injury Research and Policy and the Centers ... increased injury prevention efforts in many of the most popular ... in the United States. Injury is the leading cause of ... health efforts to promote physical activity in kids do not ...
... HealthDay Reporter , FRIDAY, Jan. 20 (HealthDay News) -- ... asthma medication use during pregnancy and common birth defects. ... some rare birth defects and mothers with asthma, and potentially ... whether the problem was a loss of oxygen from less ...
Cached Medicine News:Health News:Experts Weigh Changes to Definition of Autism 2Health News:Experts Weigh Changes to Definition of Autism 3Health News:Inflammatory mediator promotes colorectal cancer by stifling protective genes 2Health News:Inflammatory mediator promotes colorectal cancer by stifling protective genes 3Health News:Study showed oxaliplatin improved colon cancer patient survival 2Health News:Many strategies to increase physical activity for kids lack injury prevention measures 2Health News:Asthma Meds Likely Safe During Pregnancy: Study 2Health News:Asthma Meds Likely Safe During Pregnancy: Study 3
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: